Decreased nicotinic receptor availability in smokers with slow rates of nicotine metabolism

Journal of Nuclear Medicine

Volumn 56, Issue 11, 2015, Pages 1724-1729

  Dubroff, Jacob G ^a   Doot, Robert K ^a   Falcone, Mary ^a   Schnoll, Robert A ^a   Ray, Riju ^b   Tyndale, Rachel F ^c   Brody, Arthur L ^d,e   Hou, Catherine ^a   Schmitz, Alexander ^a   Lerman, Caryn ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GSK   (Belgium)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

2 18F FA 85380; Addiction; NAChR; Nicotine; Nicotine metabolite ratio; PET; 4 2

Indexed keywords

2 FLUORO 3 (2 AZETIDINYLMETHOXY)PYRIDINE F 18; NICOTINE; NICOTINIC RECEPTOR ALPHA4BETA2; TRACER; UNCLASSIFIED DRUG; 2-FLUORO-3-(2-AZETIDINYLMETHOXY)PYRIDINE; AZETIDINE DERIVATIVE; NICOTINIC RECEPTOR; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; LIVER METABOLISM; MALE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN METABOLISM; RADIOISOTOPE DECAY; RADIOISOTOPE DISTRIBUTION; SMOKING; SMOKING CESSATION; WITHDRAWAL SYNDROME; BIOAVAILABILITY; BRAIN; CRAVING; DIAGNOSTIC IMAGING; INTRAVENOUS DRUG ADMINISTRATION; KINETICS; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PSYCHOLOGY; REPRODUCIBILITY; THALAMUS; TOBACCO DEPENDENCE; YOUNG ADULT;

ADULT; AZETIDINES; BIOLOGICAL AVAILABILITY; BRAIN; CRAVING; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NICOTINE; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTORS, NICOTINIC; REPRODUCIBILITY OF RESULTS; SMOKING; THALAMUS; TOBACCO USE DISORDER; YOUNG ADULT;

EID: 84946554294     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.155002     Document Type: Article

References (48)

1. WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco. World Health Organization website. http://www.who.int/tobacco/global-report/2011/en/. Published 2011. Accessed August 27, 2015.
2. Centers for Disease Control and Prevention. Current cigarette smoking among adults: United States, 2011. Morb Mortal Wkly Rep. 2012;61:889-894.
3. Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and economic costs: United States-1995-1999. Morb Mortal Wkly Rep. 2002;14:300-303.
4. 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care. 2008;53:1217-1222.
5. Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P III. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res. 2003;5:621-624.
6. Dempsey D, Tutka P, Jacob P III, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004;76:64-72.
7. Lerman C, Tyndale R, Patterson F, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther. 2006;79:600-608.
8. Ray R, Tyndale RF, Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet. 2009;23:252-261.
9. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav. 2009;92:6-11.
10. Lerman C, Schnoll RA, Hawk LW Jr, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015;3:131-138.
11. Vaz LR, Coleman T, Cooper S, Aveyard P, Leonardi-Bee J. The nicotine metabolite ratio in pregnancy measured by trans-3'-hydroxycotinine to cotinine ratio: characteristics and relationship with smoking cessation. Nicotine Tob Res. January 14, 2015 [Epub ahead of print].
12. Piasecki TM. Relapse to smoking. Clin Psychol Rev. 2006;26:196-215.
13. Westman EC, Behm FM, Simel DL, Rose JE. Smoking behavior on the first day of a quit attempt predicts long-term abstinence. Arch Intern Med. 1997;157:335-340.
14. 3H]nicotine binding sites in human brain. J Neurochem. 1988;50:1243-1247.
15. 3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther. 1997;282:7-13.
16. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. A subtype of nico-tinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol. 1992;41:31-37.
17. Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther. 1999;289:1545-1552.
18. Whiting PJ, Lindstrom JM. Characterization of bovine and human neuronal nico-tinic acetylcholine receptors using monoclonal antibodies. J Neurosci. 1988;8: 3395-3404.
19. Brody AL, Mukhin AG, La Charite J, et al. Up-regulation of nicotinic acetylcholine receptors in menthol cigarette smokers. Int J Neuropsychopharmacol. 2013;16:957-966.
20. 18F]N-methyl-NFEP: kinetics, nicotine effect, and toxicity. Nucl Med Biol. 1999;26:139-148.
21. 18F-fluoro-A-85380 and PET. J Nucl Med. 2005;46:240-247.
22. Staley JK, Krishnan-Sarin S, Cosgrove KP, et al. Human tobacco smokers in early abstinence have higher levels of beta2 nicotinic acetylcholine receptors than nonsmokers. J Neurosci. 2006;26:8707-8714.
23. Brody AL, Mukhin AG, Shulenberger S, et al. Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density. Neuropsychopharmacology. 2013;38:1548-1556.
24. Cosgrove KP, Batis J, Bois F, et al. Beta2-nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry. 2009;66:666-676.
25. Brody AL, Mandelkern MA, London ED, et al. Effect of secondhand smoke on occupancy of nicotinic acetylcholine receptors in brain. Arch Gen Psychiatry. 2011;68:953-960.
26. Brody AL, Mandelkern MA, London ED, et al. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry. 2006;63:907-915.
27. Lotfipour S, Mandelkern M, Alvarez-Estrada M, Brody AL. A single administration of low-dose varenicline saturates alpha4beta2 nicotinic acetylcholine receptors in the human brain. Neuropsychopharmacology. 2012;37:1738-1748.
28. Lotfipour S, Mandelkern M, Brody AL. Quantitative molecular imaging of neuronal nicotinic acetylcholine receptors in the human brain with A-85380 radiotracers. Curr Med Imaging Rev. 2011;7:107-112.
29. Brody AL, Mandelkern MA, Costello MR, et al. Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. Int J Neuropsychopharmacol. 2009;12:305-316.
30. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(SUPPL. 20):22-33.
31. 18F]F-A85380. Neuroimage. 2008;39:717-727.
32. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001;3:7-16.
33. 18F]F-A-85380 in blood plasma using solid-phase extraction. Nucl Med Biol. 2007;34:221-228.
34. ∗Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175-191.
35. Benowitz NL, Perez-Stable EJ, Herrera B, Jacob P III. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst. 2002;94:108-115.
36. Benowitz NL, Swan GE, Jacob P III, Lessov-Schlaggar CN, Tyndale RF. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther. 2006;80:457-467.
37. Levi M, Dempsey DA, Benowitz NL, Sheiner LB. Population pharmacokinetics of nicotine and its metabolites I. Model development. J Pharmacokinet Pharmacodyn. 2007;34:5-21.
38. Le Foll B, Chefer SI, Kimes AS, et al. Baseline expression of alpha4beta2 nicotinic acetylcholine receptors predicts motivation to self-administer nicotine. Biol Psychiatry. 2009;65:714-716.
39. Marks MJ, McClure-Begley TD, Whiteaker P, et al. Increased nicotinic acetylcholine receptor protein underlies chronic nicotine-induced up-regulation of nicotinic agonist binding sites in mouse brain. J Pharmacol Exp Ther. 2011;337: 187-200.
40. Menossi HS, Goudriaan AE, de Azevedo-Marques Perico C, et al. Neural bases of pharmacological treatment of nicotine dependence: insights from functional brain imaging - a systematic review. CNS Drugs. 2013;27:921-941.
41. Sharma A, Brody AL. In vivo brain imaging of human exposure to nicotine and tobacco. Handb Exp Pharmcol. 2009;(192):145-171.
42. Brody AL, Mukhin AG, Mamoun MS, et al. Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial. JAMA Psychiatry. 2014;71:797-805.
43. Cosgrove KP, Esterlis I, McKee SA, et al. Sex differences in availability of b2-nicotinic acetylcholine receptors in recently abstinent tobacco smokers. Arch Gen Psychiatry. 2012;69:418-427.
44. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. New York, New York: Oxford University Press; 2003:151-179.
45. Campling BG, Kuryatov A, Lindstrom J. Acute activation, desensitization and smoldering activation of human acetylcholine receptors. PLoS One. 2013;8: e79653.
46. 18F-FA-85380. J Nucl Med. 2008;49:1628-1635.
47. Sellers EM, Ramamoorthy Y, Zeman MV, Djordjevic MV, Tyndale RF. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine Tob Res. 2003;5:891-899.
48. Siu EC, Tyndale RF. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther. 2008;324:992-999.